Bieliauskiene Giedre, Zaar Oscar, Kolmodin Isabel, Gillstedt Martin, Paoli John
Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Acta Derm Venereol. 2020 Oct 28;100(17):adv00305. doi: 10.2340/00015555-3670.
Kaposi sarcoma is a rare skin cancer, and epidemiological research into Kaposi sarcoma is therefore scarce. The current epidemiological situation for Kaposi sarcoma in Sweden is unknown. The authors hypothesized that the incidence of Kaposi sarcoma should have decreased after the introduction of antiretroviral therapy in 1996. Using data from the Swedish Cancer Registry, this study aimed to determine the incidence rates and survival for Kaposi sarcoma in Sweden from 1993 to 2016. The results showed that a total of 657 patients (74.0% men, 26.0% women) were diagnosed with Kaposi sarcoma in Sweden during 1993 to 2016. The overall incidence per 100,000, age-standardized to the world population, decreased from 0.40 to 0.10 (p = 0.003) for both sexes combined, from 0.76 to 0.14 (p=0.003) for men, and from 0.07 to 0.06 (p = 0.86) for women. The 10-year overall survival rate was significantly lower for the study population (30%) compared with the age- and sex-matched Swedish population (56%) (p < 0.00001). Over the study period, incidence rates of Kaposi sarcoma decreased significantly in men, especially during the late 1990s.
卡波西肉瘤是一种罕见的皮肤癌,因此对卡波西肉瘤的流行病学研究很少。瑞典目前卡波西肉瘤的流行病学情况尚不清楚。作者推测,1996年引入抗逆转录病毒疗法后,卡波西肉瘤的发病率应该有所下降。本研究利用瑞典癌症登记处的数据,旨在确定1993年至2016年瑞典卡波西肉瘤的发病率和生存率。结果显示,1993年至2016年期间,瑞典共有657例患者(74.0%为男性,26.0%为女性)被诊断为卡波西肉瘤。按世界人口年龄标准化后,男女合并的总体发病率每10万人从0.40降至0.10(p = 0.003),男性从0.76降至0.14(p = 0.003),女性从0.07降至0.06(p = 0.86)。与年龄和性别匹配的瑞典人群(56%)相比,研究人群的10年总生存率显著较低(30%)(p < 0.00001)。在研究期间,男性卡波西肉瘤的发病率显著下降,尤其是在20世纪90年代后期。